Skip to main content

Table 2 Percent of Patients with an Increase in Dose After One Year

From: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

  Infliximab Etanercept  
  Patients with 3+ infusions Pct with an increase in dose Patients with 3+ infusions Pct with an increase in dose p-value
Overall 598 57.9% 950 18.1% <0.001
by Pre-period RA Costs      
Quartile 1 – $0 to $502.89 157 49.7% 230 16.5% <0.001
Quartile 2 – $502.90 to $975 157 62.4% 230 18.7% <0.001
Quartile 3 – $975.15 to $176 135 57.8% 252 15.9% <0.001
Quartile 4 – $1766.22 + 149 61.7% 238 21.4% <0.001
by Year      
1999* 0 0.0% 196 22.4% <0.001
2000 309 53.1% 602 17.9% <0.001
2001 289 63.0% 152 13.2% <0.001
by Region      
East 52 53.8% 149 20.1% <0.001
South 269 60.2% 151 17.2% <0.001
Midwest 232 57.3% 545 19.4% <0.001
West 45 51.1% 105 9.5% <0.001
by Age Group      
< 18 Years 1 100.0% 39 33.3% <0.001
18 – 34 Years 42 50.0% 83 14.5% <0.001
35 – 44 Years 119 66.4% 221 16.7% <0.001
45 – 54 Years 214 60.3% 353 17.3% <0.001
55 – 64 Years 194 54.1% 238 18.9% <0.001
65 + Years 28 39.3% 16 25.0% <0.001
  1. *Infliximab dosing for RA was not detectable via HCPCS code until June of 2000